Keith Ahamad
Overview
Explore the profile of Keith Ahamad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
509
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Langlois J, Fairbairn N, Jutras-Aswad D, Le Foll B, Ahamad K, Lim R, et al.
Subst Use Addctn J
. 2024 Nov;
:29767342241298044.
PMID: 39614597
Background: It has been suggested that opioid agonist therapy (OAT) may have a secondary benefit of reducing methamphetamine/amphetamine use. However, current evidence is limited and conflicting, and little is known...
2.
Bakouni H, Haquet L, Socias M, Le Foll B, Lim R, Ahamad K, et al.
J Addict Med
. 2024 Jan;
18(2):167-173.
PMID: 38258865
Introduction: Methadone and buprenorphine/naloxone (BUP/NX) titration parameters (eg, range, duration, and rate) can vary during opioid use disorder (OUD) treatment. We describe methadone and BUP/NX titration patterns and their associations...
3.
Kazi I, Chenoweth M, Jutras-Aswad D, Ahamad K, Socias M, Le Foll B, et al.
Clin Pharmacol Ther
. 2023 Nov;
115(3):506-514.
PMID: 38009933
Methadone and buprenorphine/naloxone are opioid agonist therapies for opioid use disorder treatment. Genetic factors contribute to individual differences in opioid response; however, little is known regarding genetic associations with clinical...
4.
Duncan K, Scheuermeyer F, Lane D, Ahamad K, Moe J, Dong K, et al.
CJEM
. 2023 Aug;
25(10):802-807.
PMID: 37606738
Objectives: Many emergency department (ED) patients with opioid use disorder are candidates for home buprenorphine/naloxone initiation with to-go packs. We studied patient opinions and acceptance of buprenorphine/naloxone to-go packs, and...
5.
Bakouni H, McAnulty C, Tatar O, Socias M, Le Foll B, Lim R, et al.
Am J Addict
. 2023 Jun;
32(5):469-478.
PMID: 37308805
Background And Objectives: Buprenorphine/naloxone (BUP-NX) and methadone are used to treat opioid use disorder (OUD), yet there is insufficient evidence on the impact of doses on interventions' effectiveness and safety...
6.
Jutras-Aswad D, Le Foll B, Ahamad K, Lim R, Bruneau J, Fischer B, et al.
Am J Psychiatry
. 2022 Jun;
179(10):726-739.
PMID: 35702828
Objective: Extensive exposure to prescription-type opioids has resulted in major harm worldwide, calling for better-adapted approaches to opioid agonist therapy. The authors aimed to determine whether flexible take-home buprenorphine/naloxone is...
7.
Mong J, Ahamad K, Bach P
CMAJ
. 2021 Aug;
193(30):E1196-E1197.
PMID: 34344780
No abstract available.
8.
9.
Braithwaite V, Ti L, Fairbairn N, Ahamad K, McLean M, Harrison S, et al.
Addiction
. 2020 Dec;
116(7):1892-1900.
PMID: 33339073
Background And Aims: To improve evidence-based addiction care in acute care settings, many hospitals across North America are developing an inpatient addiction medicine consultation service (AMCS). St Paul's Hospital in...
10.
Fairgrieve C, Nosova E, Milloy M, Fairbairn N, DeBeck K, Ahamad K, et al.
Subst Abus
. 2020 Apr;
41(3):323-330.
PMID: 32348197
: Little is known about how the expansion of opioid agonist therapy (OAT) and emergence of fentanyl in the illicit drug supply in North America has influenced non-fatal opioid overdose...